Eastern Hepatobiliary Surgery Hospital
A Clinical Study of Multi-target Hi-TCR-T Cells in the Treatment of Advanced Hepatocellular Carcinoma
- Conditions
- Advanced Hepatocellular Carcinoma (HCC)
- Interventions
- Biological: Super Hi-TCR-T cells
- First Posted Date
- 2025-03-30
- Last Posted Date
- 2025-04-29
- Lead Sponsor
- Eastern Hepatobiliary Surgery Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT06902389
- Locations
- 🇨🇳
The Third Affiliated Hospital of Navy Military Medical University, Shanghai, Yangpu District, China
QL1706 Combined with Lenvatinib and GEMOX As First - Line Treatment for Unresectable Biliary Tract Tumors
- First Posted Date
- 2025-03-25
- Last Posted Date
- 2025-03-27
- Lead Sponsor
- Eastern Hepatobiliary Surgery Hospital
- Target Recruit Count
- 59
- Registration Number
- NCT06892925
- Locations
- 🇨🇳
the Third Affiliated Hospital of Naval Medical University, Shanghai, Shanghai, China
Inetetamab Plus Chemotherapy ± PD-1/PD-L1 in HER2+ Advanced Biliary Cancer
- Conditions
- Metastatic Biliary Tract CancerHER2 Positive
- Interventions
- Drug: Inetetamab + Gemcitabine + Cisplatin ± PD-1/PD-L1 inhibitor
- First Posted Date
- 2025-02-10
- Last Posted Date
- 2025-02-10
- Lead Sponsor
- Eastern Hepatobiliary Surgery Hospital
- Target Recruit Count
- 35
- Registration Number
- NCT06818773
Pemigatinib Combined With Durvalumab for Previously Treated Biliary Tract Carcinoma
- Conditions
- Biliary Tract CarcinomaCholangiocarcinoma
- Interventions
- First Posted Date
- 2024-07-31
- Last Posted Date
- 2024-07-31
- Lead Sponsor
- Eastern Hepatobiliary Surgery Hospital
- Target Recruit Count
- 38
- Registration Number
- NCT06530823
Envafolimab Combined With GEMOX in First-line Treatment of Advanced GBC
- Conditions
- Gallbladder Cancer
- Interventions
- Drug: Envafolimab+Gemox
- First Posted Date
- 2023-08-28
- Last Posted Date
- 2023-09-15
- Lead Sponsor
- Eastern Hepatobiliary Surgery Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT06013943
- Locations
- 🇨🇳
Easter hepatobiliary surgery hospital, Shanghai, Shanghai, China
Cadonilimab Plus TACE in Patients With Intermediate-stage Unresectable Hepatocellular Carcinoma
- Conditions
- Hepatocellular Carcinoma
- Interventions
- Drug: Cadonilimab+TACE
- First Posted Date
- 2023-06-29
- Last Posted Date
- 2023-06-29
- Lead Sponsor
- Eastern Hepatobiliary Surgery Hospital
- Target Recruit Count
- 41
- Registration Number
- NCT05925413
- Locations
- 🇨🇳
Eastern hepatobilliary surgery hospital, Shanghai, Shanghai, China
A Machine Learning Architecture to Predict Post-Hepatectomy Liver Failure Using Liver Regeneration Biomarkers and Time-Phased Data
- Conditions
- Liver Failure After Operative Procedure
- Interventions
- Procedure: Extensive hepatectomy
- First Posted Date
- 2023-03-22
- Last Posted Date
- 2025-05-22
- Lead Sponsor
- Shen Feng
- Target Recruit Count
- 1071
- Registration Number
- NCT05779098
- Locations
- 🇨🇳
Department of Hepatobiliary and Pancreatic Surgery, Tenth People's Hospital of Tongji University, School of Medicine, Tongji University, Shanghai, China, Shanghai, China
A Study of Danning Tablet in Patients With Polypoid Lesions of Gallbladder
- Conditions
- Polyps Gallbladder
- Interventions
- Drug: Danning Tablet
- First Posted Date
- 2022-12-30
- Last Posted Date
- 2022-12-30
- Lead Sponsor
- Eastern Hepatobiliary Surgery Hospital
- Target Recruit Count
- 336
- Registration Number
- NCT05668871
- Locations
- 🇨🇳
The First Affiliated Hospital of University of South China, Hengyang, Hunan, China
🇨🇳Eastern Hepatobiliary Surgery Hospital, Naval Medical University,, Shanghai, Shanghai, China
🇨🇳Loudi Central Hospital, Loudi, Hunan, China
AssesSment of Early-deteCtion basEd oN liquiD Biopsy in Biliary Tract Cancer (ASCEND-BTC)
- Conditions
- Biliary Tract Cancer
- Interventions
- Other: Blood drawing
- First Posted Date
- 2022-12-28
- Last Posted Date
- 2022-12-30
- Lead Sponsor
- Eastern Hepatobiliary Surgery Hospital
- Target Recruit Count
- 492
- Registration Number
- NCT05667350
- Locations
- 🇨🇳
Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China
🇨🇳Eastern Hepatobiliary Surgery Hospital, Shanghai, Shanghai, China
Vascular Invasion Signatures in cfDNA Support Re-staging of Liver Cancer
- Conditions
- Liver CancerCarcinoma, HepatocellularHepatocellular Cancer
- Interventions
- Procedure: Liver resection
- First Posted Date
- 2022-09-15
- Last Posted Date
- 2022-09-19
- Lead Sponsor
- Eastern Hepatobiliary Surgery Hospital
- Target Recruit Count
- 286
- Registration Number
- NCT05540925
- Locations
- 🇨🇳
Eastern Hepatobiliary Surgery Hospital, Naval Medical University,, Shanghai, Shanghai, China